Search research articles
Contact Us
Filters
Showing results (191-200 of 250) with videos related to
Page
of 25
Sort By:
Blood
|
May 27, 2016
Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma
Meletios A Dimopoulos, Antonio Palumbo, Paolo Corradini, et al.
Plos One
|
September 8, 2018
Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials
Lucia Lopez-Anglada, Cecilia Cueto-Felgueroso, Laura Rosiñol, et al.
Blood Cancer Journal
|
March 20, 2019
Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature
Paula Rodríguez-Otero, María Victoria Mateos, Joaquín Martínez-López, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 3, 2025
Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study
Sikander Ailawadhi, Ivan Špička, Andrew Spencer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 1, 2024
Minimally Invasive Assessment of Peripheral Residual Disease During Maintenance or Observation in Transplant-Eligible Patients With Multiple Myeloma
Marta Lasa, Laura Notarfranchi, Cristina Agullo, et al.
Leukemia
|
March 9, 2019
Correction: Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role
Paula Rodríguez-Otero, María Victoria Mateos, Joaquín Martínez-López, et al.
Blood
|
September 9, 2011
Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance
María-Victoria Mateos, Norma C Gutiérrez, María-Luisa Martín-Ramos, et al.
Haematologica
|
April 27, 2023
Randomized phase II study of weekly carfilzomib 70 mg/m<sup>2</sup> and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients
Borja Puertas, Verónica González-Calle, Anna Sureda, et al.
Journal for Immunotherapy of Cancer
|
March 6, 2026
Antibiotic-associated dysbiosis and bispecific antibody outcomes in multiple myeloma
Magdalena Corona, Roberto García-Vicente, Adolfo Jesús Saez-Marin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 22, 2022
A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable MRD and Survival Outcomes in Multiple Myeloma
Camila Guerrero, Noemi Puig, Maria-Teresa Cedena, et al.
Page
of 25
Search research articles
Search
Showing results (191-200 of 250) with videos related to
Sort By:
Page
of 25
Blood
|
May 27, 2016
Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma
Meletios A Dimopoulos, Antonio Palumbo, Paolo Corradini, et al.
Plos One
|
September 8, 2018
Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials
Lucia Lopez-Anglada, Cecilia Cueto-Felgueroso, Laura Rosiñol, et al.
Blood Cancer Journal
|
March 20, 2019
Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature
Paula Rodríguez-Otero, María Victoria Mateos, Joaquín Martínez-López, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 3, 2025
Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study
Sikander Ailawadhi, Ivan Špička, Andrew Spencer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 1, 2024
Minimally Invasive Assessment of Peripheral Residual Disease During Maintenance or Observation in Transplant-Eligible Patients With Multiple Myeloma
Marta Lasa, Laura Notarfranchi, Cristina Agullo, et al.
Leukemia
|
March 9, 2019
Correction: Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role
Paula Rodríguez-Otero, María Victoria Mateos, Joaquín Martínez-López, et al.
Blood
|
September 9, 2011
Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance
María-Victoria Mateos, Norma C Gutiérrez, María-Luisa Martín-Ramos, et al.
Haematologica
|
April 27, 2023
Randomized phase II study of weekly carfilzomib 70 mg/m<sup>2</sup> and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients
Borja Puertas, Verónica González-Calle, Anna Sureda, et al.
Journal for Immunotherapy of Cancer
|
March 6, 2026
Antibiotic-associated dysbiosis and bispecific antibody outcomes in multiple myeloma
Magdalena Corona, Roberto García-Vicente, Adolfo Jesús Saez-Marin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 22, 2022
A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable MRD and Survival Outcomes in Multiple Myeloma
Camila Guerrero, Noemi Puig, Maria-Teresa Cedena, et al.
Page
of 25